Related references
Note: Only part of the references are listed.Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Ming Yi et al.
MOLECULAR CANCER (2022)
Immunotherapies targeting stimulatory pathways and beyond
Julian A. Marin-Acevedo et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Integrated analysis of multimodal single-cell data
Yuhan Hao et al.
CELL (2021)
LFA-1 in T cell priming, differentiation, and effector functions
Audrey Gerard et al.
TRENDS IN IMMUNOLOGY (2021)
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Daixi Ren et al.
MOLECULAR CANCER (2020)
Tertiary lymphoid structures in cancer - considerations for patient prognosis
Luis Munoz-Erazo et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
The predictive value of serum soluble ICAM-1 and CXCL13 in the therapeutic response to TNF inhibitor in rheumatoid arthritis patients who are refractory to csDMARDs
Juan Zhao et al.
CLINICAL RHEUMATOLOGY (2020)
Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape
Constance J. Martin et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors
Kurt A. Schalper et al.
NATURE MEDICINE (2020)
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade
Kobe C. Yuen et al.
NATURE MEDICINE (2020)
Deciphering the response and resistance to immune-checkpoint inhibitors in lung cancer with artificial intelligence-based analysis: when PIONeeR meets QUANTIC
Joseph Ciccolini et al.
BRITISH JOURNAL OF CANCER (2020)
Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
Qingyang Lei et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
Catherine S. Grasso et al.
CANCER CELL (2020)
EVALUATION OF CXCL13 AND ICAM1 SERUM LEVELS AS PREDICTORS OF CLINICAL RESPONSE TO ABATACEPT IN RHEUMATOID ARTHRITIS.
S. Piantoni et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
The single-cell transcriptional landscape of mammalian organogenesis
Junyue Cao et al.
NATURE (2019)
Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?
P. Hofman et al.
ANNALS OF ONCOLOGY (2019)
Cytokines in clinical cancer immunotherapy
Pedro Berraondo et al.
BRITISH JOURNAL OF CANCER (2019)
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
David Liu et al.
NATURE MEDICINE (2019)
Levels of CXCL13 and sICAM-1 correlate with disease activity score in patients with rheumatoid arthritis treated with tocilizumab
Katie Tuckwell et al.
ADVANCES IN RHEUMATOLOGY (2019)
Tertiary lymphoid structures in the era of cancer immunotherapy
Catherine Sautes-Fridman et al.
NATURE REVIEWS CANCER (2019)
Mechanisms of resistance to immune checkpoint inhibitors
Russell W. Jenkins et al.
BRITISH JOURNAL OF CANCER (2018)
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
Young Kwang Chae et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
ICAM1 expression is induced by proinflammatory cytokines and associated with TLS formation in aggressive breast cancer subtypes
Stine L. Figenschau et al.
SCIENTIFIC REPORTS (2018)
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas
Zijun Y. Xu-Monette et al.
BLOOD (2018)
PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas
Aaron Goodman et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
Tawee Tanvetyanon et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2017)
Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment
Qiaohong Wang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2017)
Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy
Robert J. Torphy et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy
Junyu Long et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
An immunogenic personal neoantigen vaccine for patients with melanoma
Patrick A. Ott et al.
NATURE (2017)
SCENIC: single-cell regulatory network inference and clustering
Sara Aibar et al.
NATURE METHODS (2017)
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
Zijun Y. Xu-Monette et al.
FRONTIERS IN IMMUNOLOGY (2017)
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nisha Nagarsheth et al.
NATURE REVIEWS IMMUNOLOGY (2017)
Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade
Haidong Tang et al.
CANCER CELL (2016)
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
Frank A. Schildberg et al.
IMMUNITY (2016)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
The Molecular Signatures Database Hallmark Gene Set Collection
Arthur Liberzon et al.
CELL SYSTEMS (2015)
Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy
Denise Skrombolas et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2014)
STAR: ultrafast universal RNA-seq aligner
Alexander Dobin et al.
BIOINFORMATICS (2013)
ICAM-1-Dependent Homotypic Aggregates Regulate CD8 T Cell Effector Function and Differentiation during T Cell Activation
Nicholas A. Zumwalde et al.
JOURNAL OF IMMUNOLOGY (2013)
ICAM-1-dependent tuning of memory CD8 T-cell responses following acute infection
Maureen A. Cox et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Bo Li et al.
BMC BIOINFORMATICS (2011)
LFA-1 Contributes to Signal I of T-Cell Activation and to the Production of T(h)1 Cytokines
Georg Varga et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2010)
ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks
Gabriela Bindea et al.
BIOINFORMATICS (2009)
ICAM-1 Has a Critical Role in the Regulation of Metastatic Melanoma Tumor Susceptibility to CTL Lysis by Interfering with PI3K/AKT Pathway
Ahmed Hamai et al.
CANCER RESEARCH (2008)
A synaptic basis for paracrine interleukin-2 signaling during homotypic T cell interaction
Catherine A. Sabatos et al.
IMMUNITY (2008)
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
Arlene H. Sharpe et al.
NATURE IMMUNOLOGY (2007)
Side effects of interferon-α therapy
S Sleijfer et al.
PHARMACY WORLD & SCIENCE (2005)
Molecular signatures distinguish human central memory from effector memory CD8 T cell subsets
T Willinger et al.
JOURNAL OF IMMUNOLOGY (2005)
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
RV Parry et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
TNF-related activation-induced cytokine enhances leukocyte adhesiveness:: Induction of ICAM-1 and VCAM-1 via TNF receptor-associated factor and protein kinase c-dependent NF-κB activation in endothelial cells
JK Min et al.
JOURNAL OF IMMUNOLOGY (2005)
ICAM-1 contributes to but is not essential for tumor antigen cross-priming and CD8+ T cell-mediated tumor rejection in vivo
C Blank et al.
JOURNAL OF IMMUNOLOGY (2005)
Stimulation by soluble CD70 promotes strong primary and secondary CD8+ cytotoxic T cell responses in vivo
TF Rowley et al.
JOURNAL OF IMMUNOLOGY (2004)
Targeting ICAM-1/LFA-1 interaction for controlling autoimmune diseases: designing peptide and small molecule inhibitors
ME Anderson et al.
PEPTIDES (2003)
CXCL13 is required for B1 cell homing, natural antibody production, and body cavity immunity
KM Ansel et al.
IMMUNITY (2002)
A chemokine-driven positive feedback loop organizes lymphoid follicles
KM Ansel et al.
NATURE (2000)
The B7/CD28/CTLA4 T-cell activation pathway - Implications for inflammatory lung disease
JM Green
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2000)